Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19558165 | 0.82 | CYP19A1 (0.41) | CYP19A1CHRNB2CHRNA4HCAR2CYP11B2 | |
| SCHEMBL19251107 | 0.79 | CHRNB2 (0.35) | CYP19A1CHRNB2CHRNA4HCAR2CYP11B2 | |
| SCHEMBL799552 | 0.77 | CYP19A1 (0.41) | CYP19A1CHRNB2CHRNA4HCAR2CYP11B2 | |
| SCHEMBL19251108 | 0.77 | CNR2 (0.38) | CYP19A1CHRNB2CHRNA4 | |
| SCHEMBL22752547 | 0.74 | CNR2 (0.45) | — | |
| SCHEMBL30581493 | 0.74 | CYP11B2 (0.48) | CYP19A1HCAR2CYP11B2CYP11B1 | |
| SCHEMBL16755475 | 0.74 | CYP19A1 (0.38) | CYP19A1CHRNB2CHRNA4HCAR2CYP11B2 | |
| SCHEMBL21133837 | 0.73 | HDAC8 (0.34) | — | |
| Hydrochloric Acid SCHEMBL27566786 | 0.71 | CYP19A1 (0.42) | CYP19A1HCAR2CYP11B2CYP11B1 | |
| SCHEMBL24608378 | 0.71 | CYP2C9 (0.39) | CYP19A1CHRNB2CHRNA4HCAR2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123165-A1 | KINASE INHIBITORS | INSILICO MEDICINE LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123165-A1 | KINASE INHIBITORS | DDR1, DDR2, DDRGK1 | CYP19A1 2128/4885CHRNB2 1934/4885CHRNA4 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.